Summary
The response’s specific lab-interference claim is consistent with the provided excerpts (5.6 and 7.5), but the rest of the statements about indications, dosing/monitoring, clotting risk, and regulatory/patent exclusivity cannot be verified because only limited label text was supplied. Additionally, part of the submission includes a meta-assessment (“not_auditable”) that is not a claim about prescribing information but prevents full label alignment evaluation.
Category Scores
Accurate Statements
Eltrombopag is highly colored and can discolor patient samples, interfering with certain clinical laboratory tests (including bilirubin and creatinine); communicate with the lab and consider re-testing with other methods when results are inconsistent with clinical observations.
Supported by provided excerpts: Warnings and Precautions 5.6 (Laboratory Test Interference) and 7.5 (Interference with Clinical Laboratory Tests) stating discoloration and interference with bilirubin/creatinine, and advising to communicate with the lab and re-test using other methods.
Unsupported Statements
Eltrombopag is a thrombopoietin-receptor agonist.
No prescribing-information excerpt provided to verify this mechanism statement.
Stimulation of the thrombopoietin (TPO) receptor increases platelet counts.
No prescribing-information excerpt provided to verify this pharmacologic effect statement.
Risk of excessive platelet increases can increase clotting risk.
No prescribing-information excerpt provided to verify this risk linkage wording.
Eltrombopag can be associated with blood clotting/thrombotic events.
No prescribing-information excerpt provided to verify thrombotic-event association.
Liver-related safety considerations are a main safety issue for eltrombopag.
No prescribing-information excerpt provided to verify this as a 'main safety issue.'
The specific warnings and monitoring requirements depend on the approved indication and the country’s prescribing information.
No prescribing-information excerpt provided to support this general statement.
Eltrombopag dosing is individualized to platelet response.
No dosing/adjustment excerpts provided to verify this statement.
Eltrombopag typically includes regular blood-count monitoring.
No label excerpts provided to verify monitoring frequency.
Liver tests and other monitoring may be required.
No label excerpts provided to verify specific monitoring requirements.
Additional monitoring may be required for patients whose thrombocytopenia is linked to hepatitis C.
No label excerpts provided to verify indication-specific monitoring language.
Additional monitoring may be required for patients with underlying liver disease.
No label excerpts provided to verify liver-disease-specific monitoring language.
When other manufacturers can launch eltrombopag tablets depends on patent expiry dates.
This relates to patent law and was not provided in the prescribing information excerpts.
When other manufacturers can launch eltrombopag tablets depends on regulatory exclusivity.
This relates to regulatory exclusivity and was not provided in the prescribing information excerpts.
Regulatory exclusivity can differ from patents.
This is not prescribing-information content and was not provided in the excerpts.
Eltrombopag tablets are marketed by Novartis in some countries for treatment of low platelet counts (thrombocytopenia).
No label excerpts provided to verify marketing/label wording by country or sponsor.
Eltrombopag is marketed for thrombocytopenia caused by chronic immune (idiopathic) thrombocytopenia (ITP).
No label excerpts provided to verify FDA-approved indications.
Eltrombopag is marketed for thrombocytopenia caused by chronic hepatitis C–related thrombocytopenia.
No label excerpts provided to verify FDA-approved indications.
The exact approved uses of eltrombopag depend on the country’s label.
No label excerpts provided to verify this statement.
The provided excerpts include FDA label-style section numbering... consistent with an FDA-approved prescribing information document for eltrombopag tablets.
This is a characterization of the source documents, not a claim that can be verified against actual FDA label text within the provided excerpt.
Contradictions
Important Omissions
No boxed warnings, contraindications, or core dosing/administration details were assessed against the label because only sections 5.6 and 7.5 were provided. Material omissions would include any safety warnings (e.g., boxed warnings) or contraindications that would be needed to evaluate the broader set of safety/monitoring statements.
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
The only well-supported element is laboratory test interference (5.6/7.5). Other safety-related claims (e.g., clotting risk/thrombosis and liver safety emphasis) and dosing/monitoring generalizations were not verifiably supported by the provided label excerpts, limiting assurance of on-label accuracy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Partial Aligned
Primary Issue
Most statements are not verifiable from the provided prescribing-information excerpts; only the laboratory test interference claim aligns with the supplied 5.6/7.5 text.
Suggested Improvement
Limit label-alignment evaluation and claims to sections actually provided (5.6 and 7.5). If evaluating indications, dosing/monitoring, warnings/contraindications, provide the corresponding FDA label excerpts (including boxed warning, contraindications, and dosage/administration and monitoring sections).